The addition of chemotherapy to lung cancer surgery is now considered as the standard of
care. Solid data support postoperative chemotherapy but only few results are available in the
preoperative setting. To define which timing of perioperative chemotherapy offers the best
survival improvement, the IFCT 0002 study is conducted in France.
Phase:
Phase 3
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique